Gao, S., Hao, J. (2025). A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16442